bosentan sold brand name tracleer among others dual endothelin receptor antagonist medication used treatment pulmonary artery hypertension bosentan available filmcoated tablets mg mg dispersable tablets oral suspension bosentan used treat people moderate pulmonary arterial hypertension reduce number digital ulcers open wounds especially fingertips less commonly knuckles people systemic bosentan causes harm fetuses pregnant women must take women must become pregnant taking pregnancy category x may render hormonal contraceptives ineffective forms birth control must us available doctors follow fdamandated risk evaluation mitigation strategy rems respect risks fetuses risks causing liver damage doctor must document negative pregnancy test women prescribing drug counsel contraception give regular pregnancy high risk bosentan cause liver damage fdas rems plan also requires pretesting elevated transaminases regular testing drug bosentan also contraindicated patients taking glyburide due increased risk increased liver enzymes liver damage two agents taken use bosentan cyclosporine contraindicated cyclosporine shown markedly increase serum concentration addition risk causing birth defects causing liver damage bosentan high risk causing edema pulmonary venoocclusive disease decreasing sperm counts decreases hemoglobin common adverse effects occurring people include headache elevated transaminases edema common adverse effects people include anemia reduced hemoglobin hypersensitivity reactions skin inflammation itchiness rashes red skin flushing fainting heart palpitations low blood pressure nasal congestion gastroesophageal reflux disease bosentan may render hormonal contraceptives ineffective forms birth control must bosentan competitive antagonist endothelina eta endothelinb etb receptors normal conditions binding eta receptors causes constriction pulmonary blood conversely binding etb receptors associated vasodilation vasoconstriction vascular smooth muscle depending etb subtype bosentan blocks eta etb receptors thought exert greater effect eta receptors causing total decrease pulmonary vascular oral administration maximum plasma concentrations bosentan attained within hours terminal elimination halflife hours healthy adult subjects exposure bosentan intervenous oral administration greater adult patients pulmonary arterial hypertension healthy adult absolute bioavailability bosentan healthy peak plasma concentration bosentan dispersable tablets oral suspension less average compared peak concentration oral bosentan substrate may also play role also substrate hepatic uptake transporter organic aniontransporting polypeptides oatps elimination bosentan mostly hepatic minimal contribution renal fecal use bosentan cyclosporine contraindicated cyclosporine shown markedly increase serum concentration bosentan studied heart failure trial called terminated early due toxicity dose studied approved pulmonary artery hypertension us november european union may worldwide sales bosentan billion patents bosentan started expiring httpsenwikipediaorgwikibosentan